Introduction {#Sec1}
============

Cancer-associated anemia is a common condition reflecting a pathologic deficiency in the amount of oxygen-carrying hemoglobin in red blood cells (RBC). It is estimated that the prevalence of anemia in cancer patients before starting cancer treatment is approximately 40% (due to the disease itself, blood loss, hemolysis, bone marrow infiltration, etc.), with incidence rising to over 80% as a consequence of chemotherapy (myelosuppression by chemo- and radiotherapy, toxicity of anti-targeted therapies) \[[@CR1], [@CR2]\]. Furthermore, cancer patients may present an absolute iron deficiency (AID) due to bleeding or poor iron diet or a functional iron deficiency (FID) leading to anemia of chronic disease (ACD), likely caused by a chronic state of inflammation \[[@CR3]--[@CR5]\]. Together, these factors contribute to low hemoglobin (Hb) levels and consequently affect the patient's physical performance and QoL, disease response, and disease morbidity \[[@CR5]--[@CR8]\].

In accordance with the recommendations by the guidelines of major medical societies \[[@CR9]--[@CR12]\], current treatment for chemotherapy-associated anemia often relies on the use of erythropoietic-stimulating agents (ESAs) to reduce need of transfusion, increase Hb levels, and relieve anemia-related symptoms; yet response rates to ESA alone have been suboptimal, yielding a positive response in only 40% of patients \[[@CR4], [@CR5]\]. Several major studies \[[@CR4], [@CR13]--[@CR15]\] have demonstrated, however, that better responses in terms of increased Hb response and decreased ESA treatment time are obtained when ESA is given in combination with iron supplementation, which seems to contribute to the correction of erythropoiesis and to compensation in case of a concomitant iron deficiency \[[@CR13], [@CR16]\].

To date, iron supplementation in combination with ESAs has demonstrated to be more effective through intravenous infusion (IV), compared to conventional oral iron supplementation \[[@CR13], [@CR17]\], which would be expected in light of the recent findings on hepcidin and the limited gastrointestinal absorption of iron. According to the study by Auerbach et al. \[[@CR13]\] on cancer patients with anemia caused by iron deficiency, the percentage of response to erythropoietin (EPO) was increased by both IV and oral iron supplementation (IV 68% vs oral 36%). The study by Henry et al. on cancer patients undergoing chemotherapy evaluated the effect of IV and oral iron sulfate on patients with and without iron deficiency and found the efficacy of conventional oral supplementation to be markedly lower than IV iron \[[@CR14]\]. In the attempt of summarizing findings of published studies, a meta-analysis by Pedrazzoli et al. confirmed the efficacy of IV iron supplementation, in anemic cancer patients, in yielding best hematopoietic response with a quicker time of response and a reduction in the number of blood transfusions \[[@CR4]\]. Further insight provided by the review by Karlsson on over six clinical trials evaluating ESAs plus IV iron in cancer patients confirmed findings of previous studies, where erythropoietic response in anemic patients receiving ESA is augmented as result of IV iron supplementation \[[@CR18]\]. Finally, it appears that hematopoietic response would be related to the dose of IV iron independent of the patients' iron status \[[@CR17], [@CR19]\].

However, during the same years of these studies, the Italian Medicines Agency (AIFA) in agreement with the European Medicines Agency (EMA) released a recommendation warning on the risk of potentially fatal hyper-sensitization reactions caused by IV iron, which brought new focus onto other more effective and safer ways of iron supplementation \[[@CR20], [@CR21]\].

Recently, a new oral formulation of ferric pyrophosphate (Sideral® Forte), featuring high bioavailability (approximately threefold that of the gold standard, ferrous sulfate) and a good safety profile, has become available in most European countries \[[@CR22], [@CR23]\]. The distinguishing feature of this formulation has been assessed in a number of studies \[[@CR22], [@CR24]--[@CR27]\] and has shown to be devoid of common side effects of conventional oral iron supplementation such as stomach pain, nausea, constipation, discoloration of the mucous, and feces. Moreover, its safety has been recently confirmed in a recent randomized study on a cohort of non-anemic pregnant women \[[@CR26]\].

In the past 5 years, a number of studies have been focusing on patients with FID or AID; however, they do not consider those patients with cancer-related anemia, who have neither FID nor AID, but who still might benefit from iron supplementation. A previous study on patients with chemotherapy-related anemia and no iron deficiency has evaluated whether this patient population responded better to darbepoetin (DA) or ESA treatment with IV iron supplementation and found that iron supplementation did significantly reduce treatment failures with DA without causing additional toxicity \[[@CR15]\]. Hence, our interest focused on oral sucrosomial iron supplementation on this same type of population.

The primary aim of the present study was to perform a retrospective evaluation on the comparability in efficacy of oral sucrosomial iron supplementation in anemic cancer patients featuring neither FID nor AID and receiving darbepoetin, a relatively long-acting ESA, in comparison with IV iron supplementation in the setting of cancer supportive treatments implemented at our hospitals.

Secondary objectives were safety, effect on number of RBC units transfused, and QoL.

Materials and methods {#Sec2}
=====================

Study design and patient population {#Sec3}
-----------------------------------

This was a retrospective pilot study, performed between May 2012 and Nov 2013, involving two Oncology Departments in Southern Italy. The study considered 64 cancer patients with cancer-related anemia scheduled for chemotherapy and treatment with darbepoetin and iron supplementation.

Inclusion criteria were chemotherapy-related anemia, age ≥18 years, diagnosis of major solid tumors (breast cancer and non-small cell lung cancer), 8 \< Hb \<10 g/dL, serum ferritin ≥100 ng/mL, or transferrin saturation ≥15%, Eastern Cooperative Oncology Group Performance Score (ECOG PS) 0--2, life expectancy ≥6 months, at least 8 weeks of residual chemotherapy independent of the iron status and adequate liver and kidney function.

Exclusion criteria were AID (ferritin below the lower limit of the normal range or transferrin saturation \<10%), FID (transferrin saturation \<20% and ferritin \>100 μg/mL) \[[@CR15]\] or iron overload (transferrin saturation ≥45% and ferritin ≥800 ng/mL) upon enrolment, primary hematologic disorder causing moderate to severe anemia, bone marrow diseases, known bone marrow involvement, comorbid cardiovascular disease incompatible with ESA treatment, active infections, and ESA treatment or blood transfusions within 8 weeks.

The total observation time was 8 weeks of treatment plus 4 weeks of follow-up during which Hb and biochemical iron levels were also monitored during weekly checkup.

### Treatment {#Sec4}

Patients receiving treatment with darbepoetin alfa (500 mcg) every 3 weeks (as by treatment schedule previously established by the oncologist) were administered iron supplementation, either as IV ferric gluconate or as oral sucrosomial iron (Sideral® Forte, PharmaNutra SpA, Pisa, Italy), as established by the oncologist for a total of 8 weeks. Sucrosomial iron is a patented formulation made of ferric pyrophosphate, lecithin, and sucrester. Patients receiving IV iron were administered iron by dosages of 125 mg/week of ferric gluconate (Ferlixit, Sanofi), corresponding to two vials diluted in 250 mL of sodium chloride 0.9% in 60 min administered in the out-patient clinic of the oncology center (with emergency personnel, as required by AIFA and EMA recommendation warnings on patient safety) \[[@CR20], [@CR21]\], whereas patients receiving oral iron were given a dosage of 30 mg/day of sucrosomial iron (Sideral® Forte), corresponding to one capsule/day.

Adjustments to ESA doses were made, as appropriate, based on patient response and clinical status and in agreement with product information sheet \[[@CR28]\]: when levels of Hb were \>12 g/dL, the dose of ESA was reduced by 25--50%; when Hb were \>13 g/dL, treatment with darbepoetin was temporarily interrupted and resumed; in case of a drop of Hb values below 12 g/dL, treatment was resumed with a 25% ESA dose reduction. In the case the Hb increase was \>2 g/dL in 4 weeks, dose was reduced 25--50%.

Patients receiving IV or oral iron had consented to supplementation based on the oncologist's treatment suggestions and recommendations, as they had previously did for all other treatments. The study was conducted in line with principles outlined in the Declaration of Helsinki.

### Endpoints and measurements {#Sec5}

The endpoints measured included increase in Hb levels after administration of oral sucrosomial iron, compared to Hb levels after administration of IV ferric gluconate. Hb response was defined as Hb increase \>2 g/dL from baseline or achieving Hb ≥12 g/dL.

Secondary endpoints included parameters referring to safety profile evaluated as occurrence of adverse events (AEs) or serious adverse events (SAEs), need for transfusions (yes/no), patient response time and improvement in QoL scores.

QoL was measured by the use of standard questionnaires validated for evaluating QoL in chronic illness, namely the Functional Assessment of Cancer Therapy for anemia in cancer patients (FACT-An version 4) and the Linear Analog Self Assessment (LASA) for cancer patients during chemotherapy \[[@CR29], [@CR30]\]. Both questionnaires are patient-reported outcome tools covering functional, physical, and emotional areas, and ask patients to provide answer based on a Likert scale. Questionnaires were administered to all patients at baseline and after 8 weeks.

Patient compliance to iron supplementation was monitored during checkup by the oncologist through the patient's reports and/or by patient's request for refill of the empty blisters.

### Statistical methods {#Sec6}

Variables were expressed as mean ± standard deviation or count and proportion, depending on their distributions. Accordingly, comparisons were performed with unpaired samples *t* test or chi-squared test with continuity correction. Response curves were compared with two-way ANOVA. Computations were executed in SPSS Statistics (IBM), version 21. A value of *p* \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

The total patient population considered for the analyses consisted in 64 patients (Table [1](#Tab1){ref-type="table"}) either treated with IV iron or oral iron.Table 1Patient baseline characteristics (*n* = 64)Darbepoetin + sucrosomial ironDarbepoetin + IV iron*pn* = 33*n* = 31Sex Female, *n* (%)13 (40)12 (39)1 Males, *n* (%)20 (60)19 (61)1Type of cancer Breast, *n* (%)10 (30)10 (32)1 Lung, *n* (%)23 (70)21 (68)1Type of chemotherapy Chemo platinum, *n* (%)10 (30)12 (38)1ECOG Performance status 0, *n* (%)22 (66)19 (62)1 1, *n* (%)10 (30)10 (32)1 2, *n* (%)1 (3)2 (6)1Iron status Baseline Hb g/dL (mean)9.49.20.932

The mean baseline level of measured Hb was 9.4 g/dL in the darbepoetin + sucrosomial iron group and 9.2 g/dL in the darbepoetin + IV iron group. At least 30% of patients in each treatment group were treated with platinum-based chemotherapy, a therapy that heavily influences treatment-induced anemia compared to other types of chemotherapy.

Of all patients recruited and undergoing treatment, there were no drop-outs or cases of non- compliance to iron supplementation.

Efficacy {#Sec8}
--------

Efficacy analyses have shown that response to treatment (increase in Hb \>2 g/dL from baseline or achieving Hb ≥12 g/dL) was achieved by 71% of patients treated with IV iron and by 70% of patients supplemented with oral sucrosomial iron, with no statistically significant differences (Fig. [1](#Fig1){ref-type="fig"}). Chi-squared was equal to 0.014 with 1 degree of freedom. The two-tailed *p* value was equal to 0.9060.Fig. 1Hb response in the two treatment groups

These results support the comparability of oral sucrosomial iron supplementation versus intravenous iron in patients with chemotherapy-related anemia.

Safety {#Sec9}
------

No differences were found between the two treatment groups as to patients requiring RBC transfusion. As to adverse or serious adverse events related to iron supplementation, these were found in 6% of patients in the IV group (adverse reaction due to IV infusion) while none were found in the group supplemented with oral iron, as shown in Table [2](#Tab2){ref-type="table"}.Table 2Adverse events (AEs) and serious AEs reported in patients by treatment groupsDarbepoetin + sucrosomial iron *n* = 33Darbepoetin + IV iron *n* = 31*p*Patients with adverse events, *n* (%)13 (39)15 (48)0.636Patients with serious adverse events, *n* (%)2 (6)1 (3)1Gastrointestinal toxicity EPS-related, *n* (%)1 (3)01Infusion reaction to IV iron, *n* (%)02 (6)1Thromboembolic events, *n* (%)1 (3)1 (3)1Fatal events Overall, *n* (%)1 (3)1 (3)1 Treatment related, *n* (%)001

Overall, 43.7% of patients reported adverse events. 4.7% were serious adverse events such as gastrointestinal toxicity (abdominal pain, diarrhea) related to chemotherapy treatment (one patient in Sideral group), infusion reaction to IV iron (two patients in IV iron group), and two thromboembolic events (one per study group) most likely caused by treatment with darbepoetin. One fatal event per treatment group was reported but was not related to iron therapy.

Time to response {#Sec10}
----------------

Statistical analysis of the time to maximum response showed a comparable profile between the two treatments (*p* = 0.902) in terms of Hb increase, as reported in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Comparison of time to response (in weeks) between the two treatment groups

RBC transfusions {#Sec11}
----------------

The number of transfusions needed was equal in the two groups (one patient in each group, 3%).

QoL {#Sec12}
---

Results from the questionnaires in both patient groups showed comparable changes in quality of life parameters and compatible with a gain in Hb levels. In particular, items most specifically linked to benefits from iron (fatigue/tiredness, general weakness, shortness of breath, feeling energetic, function, being too tired to eat and motivation to perform daily chores) confirmed an improved QoL perception in both groups ([Supplemental material](#MOESM1){ref-type="media"}).

Discussion {#Sec13}
==========

Despite it is acknowledged that the use of iron supplementation in addition to ESA treatment significantly improves the hematopoietic response to ESAs in dialysis patients with chronic anemia, the use of oral supplementation in cancer patients is still suboptimal \[[@CR4]\]. In chronic illnesses, the establishment of a permanent inflammatory status leads to the production of cytokines such as IL-1α and TNF-α, that prevents EPO production from kidneys, and the pro-inflammatory cytokine IL-6 that acts on the liver and induces the production of hepcidin. This peptide plays a key role in iron homeostasis, inhibiting intestinal iron absorption and impeding the release of iron from the stores \[[@CR2], [@CR31]--[@CR33]\]. The presence of inflammation and, thus, high levels of hepcidin may limit the availability of circulating iron needed by RBC progenitors, hindering a correct erythropoiesis and eventually leading to the development of anemia of chronic disease \[[@CR5], [@CR34]\]. Thus, cancer patients, who present high or normal ferritin level, but also low circulating iron levels, may benefit from iron supplementation.

The issue of chemotherapy-induced anemia and low Hb levels in cancer patients is associated with poor physical performance status and disease-related fatigue.

Until recently (with the understanding of the mechanisms underlying FID), anemia has been largely underestimated. In 2004, an ECAM survey documented that anemia was left untreated in over 61% of cancer patients, being partly explained by a broad misconception around anemia in cancer patients (who often feature normal serum ferritin levels) and around the poor tolerability towards traditionally used iron formulations \[[@CR3], [@CR4]\], which is no longer applicable to newer formulations.

As a result of a growing number of studies on iron supplementation with ESAs \[[@CR5]\], recent guidelines on the use of these agents \[[@CR11]\] stress the importance of monitoring iron levels in patients and providing adequate supplementation in order for the patient to gain more benefit from ESA treatment, to improve Hb response, and to restore functional iron levels.

The present study specifically addressed the comparability of oral sucrosomial iron to ferric gluconate, a broadly used IV formulation, which has already been evaluated in a number of previous studies \[[@CR14], [@CR15]\] in combination with the long-acting ESA, darbepoetin.

Sucrosomial iron (Sideral®) is a preparation of ferric pyrophosphate conveyed and protected into a phospholipids and sucrester matrix. Differently from other formulations, it features low non-toxic dose of sucresters, which protect iron from the acid environment of the stomach and increase its permeability, allowing higher absorption of exogenous iron \[[@CR22], [@CR23]\]. In addition, it is characterized by an alternative route of absorption and delivery, which allows the reduction of side effects and the prevention of iron instability in the gastrointestinal tract. Preliminary studies seem to suggest that sucrosomial iron might also exert a down-regulatory effect on hepcidin in chronic inflammation \[[@CR35]\]. Taken together, these characteristics provide obvious advantages over other oral formulations, which have resulted less efficacious, compared to IV iron supplementation, in supporting Hb response in cancer patients receiving treatment with ESA.

Overall results showed comparable efficacy of sucrosomial iron to that of ferric gluconate in anemic patients not FID and not AID. Both IV and oral sucrosomial iron gave a good response rate (70 and 71%, respectively), with a maximum response rate achieved among patients with Hb \>9 g/dL and a significantly lower response rate among patients with Hb ≤9 g/dL. This could be explained by the delicate balance involved in iron homeostasis.

In reference to the time to response, oral sucrosomial iron showed a comparable result to IV iron that was maintained for the rest of the monitoring period. Time to Hb response is an important parameter to consider in cancer patients undergoing treatment with ESA. As it is well demonstrated, ESAs are associated to severe AEs (venous thromboembolism, tumor progression, stroke, and recurrence of disease) and overall mortality \[[@CR36]--[@CR38]\]. In fact, recent guidelines such as ASCO and NCCN \[[@CR10], [@CR11]\] recommend that ESA should be administered for the least amount of time and at the minimum dose possible to elicit sufficient RBC levels to limit the need to turn to blood transfusions and to improve QoL. A quicker response, thus, is desirable.

An observational study by Giordano et al. \[[@CR39]\] on sucrosomial iron in patients with sideropenic anemia confirmed the reduction of the typical side effects of a conventional martial treatment, determining at the same time an improvement of the patient's anemic condition in terms of serum iron, Hb, and ferritin \[[@CR24], [@CR25], [@CR39]\]. Another study by Pisani et al. \[[@CR27]\] in patients with chronic kidney disease demonstrated the non-inferiority of the oral sucrosomial iron compared to IV iron therapy in terms of increase in Hb levels.

From the QoL perspective, iron supplementations represent a remarkable aid in dealing with cancer-related fatigue and preventing other related symptoms such as impaired cognitive function, headache, dizziness, chest pain, shortness of breath, nausea, and depression \[[@CR6], [@CR29], [@CR30]\]. A recent German study on the overall QoL, as measured by the FACT-An total scores, showed a median anemia-related score improvement for patients receiving IV iron or ESA associated with IV iron after 12 weeks of treatment. The difference reached the level of clinical relevance (≥7 points) for patients receiving ESA associated with IV iron (106.5 to 117.5 points) \[[@CR40]\]. Likewise, the same tool, which is specifically validated for assessment in anemic cancer patients, was used also for our cohort.

All patients (both in the group of oral and IV supplementation) equally reported perceived benefits at 8 weeks. Parameters, such as fatigue/tiredness, general weakness, shortness of breath, feeling energetic, function, being too tired to eat, and motivation to perform daily chores, were all improved as expected with a gain in Hb level. Despite the small study population, such improvement quality of life represents a great achievement in patients with non-curable cancer, as it allows individuals to maintain function in daily life activities (in many cases these may also extend to family duties, work, etc.). The lack of differences in responses between the two groups is encouraging and confirms a comparable effect to IV as to benefits on QoL. Moreover, comparing the safety profile and efficacy of iron supplementations, the option of an effective oral supplementation in capsules may be less burdensome on the patient's logistics and further improve the patient's QoL, as compared to a more invasive IV iron infusion at the out-patient clinic.

From a safety point of view, the advantages of oral sucrosomial iron supplementation are even more relevant in consideration of the recent safety warning \[[@CR20], [@CR21]\] on the potentially fatal effects of IV iron infusions, making an oral iron supplementation even more desirable.

From the prospective of patient management and costs involved for the healthcare system, IV infusion has also specific procedure requirements. Firstly, each IV session requires that the hematology unit reserve a transfusion station/seat for the time required for the procedure, monitor the patient (approximately 3 h), and dedicate personnel on shift during operation, which occupies resources that could be dedicated to other duties. Considering that the need for IV iron supplementation is evaluated on a patient-to-patient basis, the frequency of supplementation might imply up to three infusions per week. Secondly, IV iron can only be performed in authorized centers equipped with emergency and intensive care professionals, which excludes many patient reference centers at local level, thus, potentially discouraging physicians and patients from supplementation.

Overall, performance of oral sucrosomial iron was comparable to that of IV iron and produced comparable advantages for patients in both functional and emotional wellbeing, and Hb levels, suggesting a potential benefit also in reducing the need for transfusions for such patients and the morbidity of the malignancy.

Limits {#Sec14}
------

The study was performed on a small sample size and was based on data from only two oncology centers, which limits the generalizability of the results.

Despite presenting an important bias given by the choice of treating both patients with iron deficit and true-replete patients with Hb \>9 g/dL, the study provided important findings on the efficacy and safety of oral sucrosomial iron in patients treated with ESA.

Taken together, our study represents a small contribution in addressing the objectives set by ASCO (and other societies thereafter) since 2007, requesting further research to be done on iron supplementation in cancer patients treated with ESA and on iron formulation.

Conclusions {#Sec15}
===========

Oral sucrosomial iron supplementation in association to darbepoetin has shown comparable efficacy to IV ferric gluconate associated to ESA in the treatment of chemotherapy-related anemia. Moreover, in consideration of the recent safety warning on IV iron and its potential serious adverse events, oral sucrosomial iron represents a valid alternative to the more invasive IV iron supplementation.

The sophisticated sucrosomial technology allows a higher absorption and bioavailability of iron with minimal side effects on the gastrointestinal tract.
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